Skip to content

Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation

Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation: a Multicenter, Parallel-group, Open-label, Non-inferiority Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07692490
Acronym
ARANMP-LT
Enrollment
170
Registered
2026-07-09
Start date
2026-07-07
Completion date
2028-10-06
Last updated
2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Allograft Dysfunction, Ischemia-Reperfusion Injury, Liver Transplantation (LT)

Keywords

Liver Transplantation, Normothermic Machine Perfusion, Ischemia-Reperfusion Injury, Early Allograft Dysfunction, Organ Preservation, Liver Graft

Brief summary

The ARANMP-LT study is a multicenter, open-label, randomized, parallel-group, non-inferiority clinical trial designed to evaluate whether avoiding graft recooling after normothermic machine perfusion (NMP) improves early outcomes following liver transplantation. Although graft recooling before implantation is common practice, experimental and preliminary clinical evidence suggests that abrupt temperature changes may contribute to ischemia-reperfusion injury. Adult recipients of deceased-donor liver grafts preserved with NMP or sequential hypothermic-normothermic machine perfusion (SHNMP) will be randomized in a 1:1 ratio to either standard graft implantation with recooling using cold preservation solution (control group) or implantation without recooling using a room-temperature 5% albumin flush immediately before reperfusion (intervention group). The primary objective is to compare the incidence of Early Allograft Dysfunction (EAD), defined according to the Olthoff criteria, between the two treatment groups. Secondary objectives include evaluation of histopathological ischemia-reperfusion injury using the Suzuki score, vascular and biliary complications, primary non-function, post-reperfusion syndrome, patient and graft survival, length of intensive care unit and hospital stay, perioperative transfusion requirements, and safety outcomes. A total of 170 participants will be enrolled across multiple Italian liver transplant centers and followed for 90 days after transplantation.

Interventions

PROCEDURENo Recooling Before Liver Implantation

After completion of normothermic machine perfusion, the liver graft is flushed with 5% albumin solution at room temperature (20-25°C) and implanted without recooling. The graft remains at near-normothermic temperature throughout the transition from ex vivo perfusion to in situ implantation, avoiding the conventional cold preservation flush before reperfusion.

PROCEDURETraditional Recooling Before Liver Implantation

After completion of normothermic machine perfusion, the liver graft undergoes the standard preservation procedure consisting of a cold preservation solution flush before implantation, resulting in graft recooling prior to reperfusion. The remainder of the transplantation procedure follows standard clinical practice.

Sponsors

The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years. * Listed for primary liver transplantation at the participating institution. * Assigned a liver graft preserved with normothermic machine perfusion or sequential hypothermic- normothermic machine perfusion (SHNMP). * Signed and dated informed consent prior study inclusion.

Exclusion criteria

* Pediatric patients (age \< 18 years) * Patients undergoing re-transplantation (history of previous liver transplantation) * Patients with acute liver failure * Patients undergoing multi-organ transplantation (e.g., liver-kidney, liver-heart) * Temporarily unconscious patients * Patients unable to freely express consent.

Design outcomes

Primary

MeasureTime frameDescription
Early Allograft Dysfunction (EAD)Within 7 days after liver transplantationIncidence of Early Allograft Dysfunction (EAD), defined according to the Olthoff criteria as bilirubin ≥10 mg/dL or INR ≥1.6 on postoperative day 7, or AST/ALT \>2000 IU/L within the first 7 postoperative days.

Countries

Italy

Contacts

CONTACTSalvatore Gruttadauria
sgruttadauria@ismett.edu0912192618
CONTACTMonica Rizzo
ufficioricerca@ismett.edu0912192692

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026